Under the terms of the deal, Recipharm will invest €15 million to take a 51% stake in the newly created company, called Resyca, while Medspray will transfer to the jv its soft mist intellectual property relating to pharmaceutical uses.

Recipharm said the technology could potentially eliminate the need for propellants by delivering therapies deep into the lungs more effectively at lower doses with less ending up in the mouth and throat.

Jean-François Hilaire, Recipharm’s European vice president strategy and global integration, said the jv “represented another piece in the jigsaw to build Recipharm into a world-leading integrated device development and manufacturing provider.” He added that the company is already seeing significant interest in such technologies and expressed his confidence that the combination of Medspray’s knowhow in spray nozzle technology and Recipharm’s device and pharmaceutical expertise would provide a “unique offering to the market.”

Resyca will operate development facilities in Munich, Germany, with Medspray supplying the spray nozzles from its site at Enschede. 

Recipharm expects to manufacture the devices across its affiliated network, including at its specialist facility in Kings’s Lynn, UK. The CDMO will also receive an exclusive license to offer customers the development and manufacturing of syringe-based devices using the soft mist nozzle technology. It will market these devices under the brand Bespak.

Author: Elaine Burridge, Freelance Journalist